23andMe (NASDAQ:ME) Given "Sell (E+)" Rating at Weiss Ratings

23andMe (NASDAQ:ME - Get Free Report)'s stock had its "sell (e+)" rating reissued by equities researchers at Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.

23andMe Stock Performance

NASDAQ:ME traded down $0.06 during mid-day trading on Friday, reaching $2.53. The stock had a trading volume of 230,940 shares, compared to its average volume of 215,517. The business has a 50 day simple moving average of $3.41 and a 200 day simple moving average of $5.05. 23andMe has a twelve month low of $2.48 and a twelve month high of $16.52. The firm has a market capitalization of $66.08 million, a price-to-earnings ratio of -0.16 and a beta of 1.14.

23andMe (NASDAQ:ME - Get Free Report) last posted its quarterly earnings results on Tuesday, January 28th. The company reported ($1.02) earnings per share for the quarter. 23andMe had a negative return on equity of 145.99% and a negative net margin of 183.39%.

Hedge Funds Weigh In On 23andMe

Several institutional investors and hedge funds have recently modified their holdings of ME. Leavell Investment Management Inc. purchased a new position in 23andMe during the fourth quarter worth approximately $32,000. MassMutual Private Wealth & Trust FSB purchased a new position in shares of 23andMe in the 4th quarter worth $40,000. FNY Investment Advisers LLC acquired a new position in 23andMe in the fourth quarter valued at $26,000. Geode Capital Management LLC grew its position in 23andMe by 0.7% during the third quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company's stock valued at $1,476,000 after acquiring an additional 28,252 shares during the period. Finally, FMR LLC increased its stake in 23andMe by 24.0% during the third quarter. FMR LLC now owns 993,848 shares of the company's stock worth $345,000 after acquiring an additional 192,099 shares during the last quarter. Hedge funds and other institutional investors own 36.10% of the company's stock.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.